Nouscom Banks $135 Million to Advance Cancer Vaccine NOUS-209
Nouscom has raised $135 million to advance NOUS-209, its lead off-the-shelf cancer vaccine — one of the larger biotech rounds of the current funding cycle.
Topic
Cancer Immunotherapy
Topic
Cancer Immunotherapy
Nouscom Raises €120 Million for Cancer Immunotherapy Push
Swiss biotech Nouscom has raised €120 million to advance its innovative cancer immunotherapy toward clinical trials, EU-Startups…